Contact us

Injectable Forms Fill and Finish CDMO Services

Specialized Aseptic Fill and Finish Solutions for Your Injectables

Showing 52 facilities
Laboratorio REIG JOFRE, SA (TOLEDO PLANT)
Spain

Laboratorio REIG JOFRE, SA (TOLEDO PLANT)

LABORATORIO REIG JOFRE SA

Betalactam antibiotics (FDF) development and manufacturing state-of-the-art facilities.

MARKETS: EMA (EU), ANVISA (Brazil), ISP (Chile), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), INVIMA (Colombia), SFDA (Saudi Arabia), TGA (Australia)

REGION: APAC, MENA, LATAM, Europe, North America

COMPLIANCE: DIGEMID, ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

BATCH SIZE: Large, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (J) Antiinfectives for systemic use

CONTROLLED SUBSTANCES: Lowest potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

White Raven - Legiapark
Belgium

White Raven - Legiapark

White Raven

Fill and finish site dedicated to GMP Formulation and the Aseptic filling of Sterile Liquid Injectables.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU)

REGION: Europe

USE: Human

BSL (Biological Safety Level): 1, 2

SERVICES: Manufacturing services, Packaging

BATCH SIZE: Small, Medium

COMPLIANCE: EMA (EU GMP)

CATEGORY / PRODUCT: BIOLOGICS, FDF / DRUG PRODUCTS

Laboratorio REIG JOFRE, SA (BARCELONA PLANT)
Spain

Laboratorio REIG JOFRE, SA (BARCELONA PLANT)

LABORATORIO REIG JOFRE SA

Injectable (lyo and liquid) and Liquid manufacturing facilities.

BSL (Biological Safety Level): 3, 1, 2

MARKETS: EMA (EU), PMDA (Japan), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MHRA (UK), INVIMA (Colombia), MFDS (South Korea), TGA (Australia)

REGION: Europe

BATCH SIZE: Large, Medium

USE: Human, Veterinary

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (N) Nervous system, (R) Respiratory system, (A) Digestive tract and metabolism

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

COMPLIANCE: PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), ECOVADIS, INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Upperton Pharma Solutions
United Kingdom

Upperton Pharma Solutions

Upperton Pharma Solutions

Development and manufacturing of oral solid dose (OSD), nasal, inhalation, and sterile dry powders and liquids drug products.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), FDA (USA), Health Canada (Canada), MHRA (UK), TGA (Australia)

REGION: Europe

USE: Human

CATEGORY / PRODUCT: OLIGONUCLEOTIDES, BIOLOGICS, SERVICES, FDF / DRUG PRODUCTS

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (N) Nervous system, (R) Respiratory system

BATCH SIZE: Small, Medium

COMPLIANCE: MHRA (UK GMP)

HIPRA BIOTECH SERVICES | Amer
Spain

HIPRA BIOTECH SERVICES | Amer

HIPRA Biotech Services

End-to-end internal capabilities from cell line development to commercial manufacturing.

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia)

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1, 2

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: BIOLOGICS, FDF / DRUG PRODUCTS

BAG Health Care
Germany

BAG Health Care

BAG Health Care GmbH

Parenteral F&F provider for vials in small to mid sized batches.

MARKETS: EMA (EU), MHRA (UK), TGA (Australia)

REGION: Europe

USE: Human, Veterinary

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

BATCH SIZE: Small, Medium

COMPLIANCE: EMA (EU GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Lifecore Injectables CDMO
United States

Lifecore Injectables CDMO

Lifecore Biomedical

CDMO that manufactures clinical & commercial sterile injectable drug products.

BSL (Biological Safety Level): 3, 1, 2

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CONTROLLED SUBSTANCES: Lowest potential for abuse

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

REGION: North America

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

EVER Pharma Jena GmbH
Germany

EVER Pharma Jena GmbH

EVER Neuro Pharma GmbH

Specialized CDMO for development and production of small molecules injectables.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human

BSL (Biological Safety Level): 1, 2

THERAPEUTIC AREAS OF EXPERTISE (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins, (L) Antineoplastic and immunomodulating agents, (N) Nervous system

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Avara Pharmaceutical Services | Liscate Site (Italy)
Italy

Avara Pharmaceutical Services | Liscate Site (Italy)

AVARA

Sterile fill-finish manufacturing site for injectable drug products (vials, ampoules, lyophilized).

BSL (Biological Safety Level): 3, 1, 2

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), ANVISA (Brazil), Russian Health Authorities, MHRA (UK), MFDS (South Korea)

REGION: Europe

BATCH SIZE: Large, Small, Medium

USE: Human

SERVICES: Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (N) Nervous system, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: SERVICES, FDF / DRUG PRODUCTS

Bilthoven Biologicals Drug Substance and Drug Product Facilities
Netherlands

Bilthoven Biologicals Drug Substance and Drug Product Facilities

Bilthoven Biologicals

Multi-product GMP facilities for Drug Substance and Drug Product.

MARKETS: EMA (EU), MHRA (UK)

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

BATCH SIZE: Large, Small, Medium

USE: Human

BSL (Biological Safety Level): 1, 2

COMPLIANCE: EMA (EU GMP)

CATEGORY / PRODUCT: BIOLOGICS, SERVICES, FDF / DRUG PRODUCTS

CZ Vaccines | Large Scale Plant Portugal
Portugal

CZ Vaccines | Large Scale Plant Portugal

CZ Vaccines

Commercial Scale Facility

MARKETS: EMA (EU)

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: ISO, EMA (EU GMP), World Health Organization (GMP / HACCP)

BATCH SIZE: Large, Medium

USE: Human

BSL (Biological Safety Level): 1, 2

THERAPEUTIC AREAS OF EXPERTISE (ATC): (J) Antiinfectives for systemic use, (R) Respiratory system, (G) Genito urinary system and sex hormones

CATEGORY / PRODUCT: BIOLOGICS, FDF / DRUG PRODUCTS

MARKETS: EMA (EU), ANVISA (Brazil), CDSCO (India)

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: ISO, ANVISA (Brazil B-GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)

USE: Human

BSL (Biological Safety Level): 1, 2

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

BATCH SIZE: Small

CATEGORY / PRODUCT: BIOLOGICS, FDF / DRUG PRODUCTS

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+21 more facilities

Create free account

Injectable drug products demand the highest standards of manufacturing to ensure safety, sterility, and efficacy. Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) specializing in aseptic fill and finish provide comprehensive solutions tailored to the unique challenges of injectable drug production. From precise formulation to final packaging, these organizations play a crucial role in meeting the rigorous requirements of the pharmaceutical and biotech industries.


Why Choose an Sterile Fill and Finish CDMO?

Injectable drugs are a cornerstone in critical therapeutic areas such as oncology, cardiology, and immunology. Manufacturing these products requires stringent aseptic processing, sterility assurance, and compliance with global regulatory standards. Partnering with a specialized sterile fill and finish CMO ensures not only product quality and safety but also an accelerated time to market.

Fill and finish services involve the meticulous preparation and packaging of injectable products in sterile environments to avoid contamination. This process is particularly vital for biologics, vaccines, and other sensitive formulations that demand precise handling. CMOs specializing in sterile manufacturing bring advanced capabilities and proven expertise to handle complex requirements, making them indispensable partners in injectable drug manufacturing.


Core Services in Aseptic Fill and Finish CDMOs

Aseptic Filling for Vials, Syringes, and Ampoules: CDMOs use state-of-the-art filling technologies to ensure accurate and sterile filling of various containers. Whether it’s small-batch production for clinical trials or large-scale manufacturing, these organizations offer flexibility and scalability.

Lyophilization (Freeze-Drying): Freeze-drying is a critical process for improving the stability and shelf life of sensitive biologics. CMOs/CDMOs with lyophilization expertise provide end-to-end solutions, from development to commercial-scale production.

Sterile Manufacturing: High-containment facilities are essential for producing cytotoxics, biologics, and other sterile products. CMOs/CDMOs equipped with these capabilities ensure compliance with stringent sterility requirements.

Analytical and Quality Testing: Comprehensive testing services are integral to aseptic fill and finish. These include sterility testing, endotoxin analysis, and stability studies, ensuring each batch meets regulatory standards.

Packaging and Labeling: Patient-friendly and tamper-evident packaging is crucial for injectable products. CMOs/CDMOs offer customizable solutions to meet diverse market needs, enhancing product safety and usability.


Key Advantages of Partnering with a Fill and Finish CMO

  1. Expertise in Sterile Processing: Aseptic fill and finish CMOs leverage advanced technologies such as isolators, restricted access barrier systems (RABS), and automated filling lines to minimize contamination risks.

  2. Regulatory Compliance: These organizations maintain compliance with global regulatory standards, including FDA, EMA, and WHO GMP guidelines, ensuring seamless market entry.

  3. Flexibility and Scalability: Whether you require small-scale production for clinical trials or high-volume commercial manufacturing, CMOs/CDMOs offer flexible solutions to match project requirements.

  4. Advanced Technologies: Innovative aseptic techniques, such as single-use systems and continuous processing, enhance production efficiency while reducing contamination risks.

  5. Focus on Biologics and Complex Formulations: Many aseptic fill and finish CDMOs specialize in biologics, peptides, and other complex molecules, providing tailored solutions for sensitive products.

  6. Faster Time to Market: Streamlined processes and experienced teams help reduce lead times, enabling pharmaceutical companies to bring products to market faster.


Industry Trends in Aseptic Fill and Finish

The aseptic fill and finish landscape is continuously evolving, driven by advances in technology and the growing demand for injectable therapies. Some key trends include:

  • Adoption of Single-Use Technologies: Single-use systems are becoming increasingly popular for their ability to reduce cleaning validation requirements and cross-contamination risks.

  • Continuous Manufacturing: This approach improves production efficiency and consistency, particularly for high-demand products.

  • Automation and Robotics: Automated filling lines and robotics enhance precision and sterility, minimizing human intervention.

  • Personalized Medicine: The rise of personalized therapies requires flexible aseptic solutions capable of handling small, customized batches.


Leading CMOs in Injectable Manufacturing

Some top-tier CMOs specializing in injectables Fill and Finish include:

  • Cenexi: CDMO specialized in the manufacture and filling of injectable and non-injectable sterile liquid products. [See CDMO profile]

  • Reig Jofre: Able to develop and manufacture sterile liquids in glass vials (aseptic filling) and sterile lyophilizates in glass vials (aseptic filling and freeze-drying). [See CDMO profile]

  • Liof Pharma: First-class partner in the field of pharmaceutical contract manufacturing, with expertise in pharmaceutical R&D, aseptic filling, lyophilization, Micro/Nanoencapsulation processes and extensive knowledge of international requirements. [See CDMO profile]

  • VIVUNT PHARMA: Manufacturing of sterile oncology drugs in liquid and lyophilized vials. [See CMO profile]

  • Ascil Biopharm: A fully equipped for R&D and pharmaceutical development GMP facility that includes laboratories and a pilot plant for technical and clinical batches of sterile products. [See CDMO profile]

  • Huiyu Pharmaceuticals Co., Ltd: Dedicated to the development and production of complex and high-value dosage forms. [See CDMO profile]

  • i+Med: Developer and manufacturer of new drug products with controlled-release technologies. [See CDMO profile]

  • Aenova Group: Competence center for animal health products and sterile technologies. [See CDMO profile]

  • HIPRA BIOTECH SERVICES: End-to-end internal capabilities from cell line development to commercial manufacturing. [See CDMO profile]

  • Basic Pharma Manufacturing: Can bring pharmaceuticals from lab scale to early clinical phase and beyond. [See CDMO profile]

  • Adragos Pharma: Specialized in aseptic manufacturing of lyophilized or liquid sterile (bio)pharmaceutical products through fill & finish. [See CDMO profile]

  • CZ Vaccines: Clinical trials facility. [See CDMO profile]

  • BAG Health Care: Parenteral fill & finish provider for vials in small- to mid-sized batches. [See CDMO profile]

  • White Raven: Fill-and-finish site dedicated to GMP-compliant formulation and the aseptic filling of sterile liquid injectable products. [See CDMO profile]

  • Bilthoven Biologicals Drug Substance and Drug Product Facilities: Multi-product GMP facilities for Drug Substance and Drug Product. [See CDMO profile]

  • PRASFARMA: CMO/CDMO specialized in cytostatics and high potency products. [See CDMO profile]

  • Ascendia Pharmaceutical Solutions: GMP-certified CDMO for advanced sterile and non-sterile pharmaceutical manufacturing, formulation development, and analytical testing. [See CDMO profile]

  • Lifecore Injectables CDMO: Clinical and commercial manufacturing of sterile injectable drug products. [See CDMO profile]

  • CDM Lavoisier: Specialized in the manufacturing of glass ampoules, glass vials and plastic (BFS) ampoules. [See CDMO profile]


Partner with MAI CDMO for Injectable Fill and Finish Solutions

At MAI CDMO, we connect you with the best Fill and Finish CMO solutions for injectable forms. Our network includes companies with proven expertise in aseptic fill and finish, sterile manufacturing, and regulatory compliance. Whether you need small-batch production for clinical trials or high-volume manufacturing for commercialization, we can help you find the right partner.

Our personalized approach ensures that your injectable project is matched with a CMO capable of meeting your unique needs. From biologics to biosimilars, our network offers advanced solutions tailored to your pharmaceutical goals.

 

Contact us today to learn more about our injectable fill and finish solutions and how we can support your pharmaceutical needs. Let us help you bring your injectable products to market with confidence and efficiency.